T. Rowe Price Associates’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-5,451,998
| Closed | -$67.8M | – | 2635 |
|
|
2016
Q4 | $67.8M | Sell |
5,451,998
-567,990
| -9% | -$6.84M | 0.01% | 710 |
|
|
2016
Q3 | $82.4M | Buy |
6,019,988
+5,945,688
| +8,002% | +$59.7M | 0.02% | 632 |
|
|
2016
Q2 | $549K | Hold |
74,300
| – | – | ﹤0.01% | 1926 |
|
|
2016
Q1 | $475K | Buy |
74,300
+11,900
| +19% | +$66.7K | ﹤0.01% | 1994 |
|
|
2015
Q4 | $390K | Buy |
62,400
+400
| +0.6% | +$2.63K | ﹤0.01% | 2061 |
|
|
2015
Q3 | $362K | Hold |
62,000
| – | – | ﹤0.01% | 2078 |
|
|
2015
Q2 | $513K | Hold |
62,000
| – | – | ﹤0.01% | 1988 |
|
|
2015
Q1 | $511K | Buy |
62,000
+14,500
| +31% | +$107K | ﹤0.01% | 1964 |
|
|
2014
Q4 | $326K | Hold |
47,500
| – | – | ﹤0.01% | 2138 |
|
|
2014
Q3 | $257K | Hold |
47,500
| – | – | ﹤0.01% | 2221 |
|
|
2014
Q2 | $303K | Hold |
47,500
| – | – | ﹤0.01% | 2174 |
|
|
2014
Q1 | $383K | Hold |
47,500
| – | – | ﹤0.01% | 2030 |
|
|
2013
Q4 | $324K | Sell |
47,500
-469,500
| -91% | -$2.53M | ﹤0.01% | 2107 |
|
|
2013
Q3 | $9.51M | Sell |
517,000
-758,250
| -59% | -$14.7M | ﹤0.01% | 1283 |
|
|
2013
Q2 | $22.3M | Buy |
+1,275,250
| New | +$22.6M | 0.01% | 1039 |
|
Other funds holding ARIA
T. Rowe Price Associates's ARIA Position: Q1 2017 in Review
T. Rowe Price Associates sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 5,451,998 shares — an estimated $67.8M sold.
T. Rowe Price Associates first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $82.4M in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- T. Rowe Price Associates reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- T. Rowe Price Associates sold 5,451,998 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $67.8M.
- T. Rowe Price Associates first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- T. Rowe Price Associates's Ariad Pharmaceuticals Inc position peaked at $82.4M in Q3 2016.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on T. Rowe Price Associates's 13F filing for Q1 2017, filed 15 May 2017.